Scholarlink

Background <p>Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control.</p> Methods <p>This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.</p> Results <p>The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3–76.6). During the median follow-up of 17.8&#xa0;months (range, 1.7–69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% (<i>P</i> = 0.008), 64.6% vs. 0% (<i>P</i> &lt; 0.001), and 97.0% vs. 85.7% (<i>P</i> = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051–30.124, <i>P</i> = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% (<i>P</i> = 0.015) and 85.7% vs. 94.6% (<i>P</i> = 0.015), respectively.</p> Conclusions <p>Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月16日

查看全文
  • Masashi Tamaoki,
  • Akira Yokoyama,
  • Chikatoshi Katada,
  • Kenshiro Hirohashi,
  • Yosuke Mitani,
  • Yusuke Amanuma,
  • Takahiro Horimatsu,
  • Hirokazu Higuchi,
  • Natsuko Yamahigashi,
  • Motoo Nomura,
  • Hiroyuki Inoo,
  • Katsuyuki Sakanaka,
  • Mitsuhiro Nikaido,
  • Takahiro Shimizu,
  • Yo Kishimoto,
  • Shigeru Tsunoda,
  • Kazutaka Obama,
  • Shinya Ohashi,
  • Manabu Muto

摘要

Background

Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control.

Methods

This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.

Results

The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3–76.6). During the median follow-up of 17.8 months (range, 1.7–69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% (P = 0.008), 64.6% vs. 0% (P < 0.001), and 97.0% vs. 85.7% (P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051–30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% (P = 0.015) and 85.7% vs. 94.6% (P = 0.015), respectively.

Conclusions

Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.